The effect of continuous and intermittent intravenous infusion of furosemide in the treatment of children with edema of nephrotic syndrome origin

Comparison between two methods of administration continuous and intermittent intravenous infusion of Furosemide in the treatment of nephrotic syndrome children with edema

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250131064573N1

Enrollment

Registered

2025-03-02

Start date

2025-03-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic nephritic syndrome. Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis

Interventions

Intervention 1: In the intervention group, patients will receive furosemide at a dosage of 0.3 to 0.5 mg per kilogram daily, administered as a continuous intravenous infusion. Intervention 2: Control

Eligibility

Sex/Gender

All

Age

2 Years to 12 Years

Inclusion criteria

Inclusion criteria: Age less than 18 years Failure to receive Furosemide before entering the plan No heart failure based on initial assessment There are no absolute contraindications to receiving intravenous furosemide Consent letter for study entry from the child's parents or legal guardian

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The patient's weight changes. Timepoint: The patient's weight changes are measured at the time of receiving the medication 24 hours later and then daily. Serum creatinine levels, fluid intake, and sodium intake are also checked at the beginning of hospitalization and then daily. Sodium should be restricted to less than 1500 mg per day. Method of measurement: Patients will be monitored daily, and the clinical condition and weight of each patient will be recorded in the information checklist until the last day of hospitalization. Additionally, baseline laboratory criteria and 24-hour urine output will be noted on days 1, 2, and 3. The need for intravenous albumin, the total dose received, and the duration of hospitalization will also be documented. Urine output will be recorded by collecting urine in a graduated container and weighing diapers in infants. Furthermore, the volume of fluids administered orally or via intravenous serum for patients with oral intolerance will be tracked. Patients will be weighed every morning at 7:00 AM using the ward's digital scale.	—

Measure

Time frame

The patient's weight changes. Timepoint: The patient's weight changes are measured at the time of receiving the medication 24 hours later and then daily. Serum creatinine levels, fluid intake, and sodium intake are also checked at the beginning of hospitalization and then daily. Sodium should be restricted to less than 1500 mg per day. Method of measurement: Patients will be monitored daily, and the clinical condition and weight of each patient will be recorded in the information checklist until the last day of hospitalization. Additionally, baseline laboratory criteria and 24-hour urine output will be noted on days 1, 2, and 3. The need for intravenous albumin, the total dose received, and the duration of hospitalization will also be documented. Urine output will be recorded by collecting urine in a graduated container and weighing diapers in infants. Furthermore, the volume of fluids administered orally or via intravenous serum for patients with oral intolerance will be tracked. Patients will be weighed every morning at 7:00 AM using the ward's digital scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Saadat

Mashhad University of Medical Sciences

SaadatS@mums.ac.ir+98 51 3882 8883

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026